COO Q4 Deep Dive: Margin Gains Offset Slower Organic Growth and Asia Pacific Pressures

Medical device company CooperCompanies (NASDAQ:COO) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.2% year on year to $1.02 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.33 billion at the midpoint. Its non-GAAP profit of $1.10 per share was 6.9% above analysts’ consensus estimates.

Is now the time to buy COO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

CooperCompanies’ fourth quarter was met with a negative market reaction, as investors focused on the company’s slower organic revenue growth and ongoing challenges in the Asia Pacific region. While management cited robust product launches and improved profitability, CEO Albert White acknowledged that legacy hydrogel product softness in Japan was a key factor holding back growth. The company benefited from operational changes and technology-driven efficiencies, with White stating, “The organizational changes and IT implementations we completed last year are generating meaningful synergies, providing us with the opportunity to invest in sales and marketing initiatives while still delivering outstanding financial performance.”

Looking ahead, CooperCompanies is banking on continued momentum from new product rollouts and disciplined capital allocation to drive improved results. Management highlighted the ramp-up of MyDay and MiSight launches in multiple regions, as well as reinvestment in sales and marketing, as core levers for growth. CFO Brian Andrews noted that operational improvements and cost efficiencies are expected to support higher margins and free cash flow, while White emphasized, “We’re investing in growth and innovation, repurchasing shares and reducing debt.” However, management cautioned that Asia Pacific headwinds may persist in the near term, with a return to regional growth expected later in the year as new launches gain traction.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to strong product performance in premium contact lenses, operational efficiencies, and targeted investments, but flagged Japan as a notable weak spot.

• Premium lens launches drive growth: Expansion of the MyDay daily silicone hydrogel portfolio, particularly MyDay multifocal and Energys, contributed to solid branded sales, with MyDay products posting double-digit growth and continued momentum from new private label contracts.
• Asia Pacific softness persists: Performance in Asia Pacific declined due to weaker demand for older hydrogel products in Japan, which offset gains from new launches. Management is addressing this with increased investment and leadership changes, aiming for recovery in later quarters.
• Operational restructuring boosts margins: Cost savings and technology adoption, including increased use of AI in back office operations, led to improved operating margins and enabled reinvestment in sales and marketing without sacrificing profitability.
• Myopia control remains a growth engine: The MiSight portfolio grew 23%, supported by new launches in Europe and Japan, and is positioned as a long-term driver given high rates of myopia in pediatric populations, especially in Asia.
• CooperSurgical sees early recovery signs: The fertility business showed initial improvement, driven by new product launches and contract wins, though uncertainty in the Middle East remains a risk for sustained momentum.

Drivers of Future Performance

CooperCompanies’ outlook is shaped by expectations for improved regional execution, new product launches, and ongoing cost discipline, while closely monitoring persistent Asia Pacific pressures.

• New product ramp-up: Management expects expanded availability of MyDay and MiSight products to drive growth, particularly in EMEA and the Americas, as recent contract wins and launches begin to positively impact sales over the next several quarters.
• Asia Pacific as a swing factor: The company anticipates Asia Pacific will remain a headwind in the near term, mainly due to legacy hydrogel product declines in Japan, but forecasts a return to growth in the region once new product introductions and leadership changes take hold.
• Operational efficiency focus: Continued leverage of AI and technology-driven process improvements is expected to support margin expansion and higher free cash flow, allowing for increased investment in strategic growth areas and potential acceleration of share repurchases.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace of recovery in Asia Pacific, especially Japan, as new leadership and product launches aim to reverse recent declines; (2) further traction from MyDay and MiSight rollouts in EMEA and the Americas and their ability to drive above-market growth; and (3) the impact of ongoing operational efficiencies on margin expansion and free cash flow. Updates on the strategic review and competitive developments in the fertility and myopia control markets will also be key markers for execution.

CooperCompanies currently trades at $78.14, down from $80.20 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.